Abstract
Background: The hypoxia-induced pro-proliferative and anti-apoptotic characteristics of pulmonary arterial endothelial cells (PAECs) play critical roles in pulmonary vascular remodeling and contribute to hypoxic pulmonary arterial hypertension (PAH) pathogenesis. However, the mechanism underlying this hypoxic disease has not been fully elucidated.Methods: Bioinformatics was adopted to screen out the key hypoxia-related genes in PAH. Gain- and loss-function assays were then performed to test the identified hypoxic pathways in vitro. Human PAECs were cultured under hypoxic (3% O2) or normoxic (21% O2) conditions. Hypoxia-induced changes in apoptosis and proliferation were determined by flow cytometry and Ki-67 immunofluorescence staining, respectively. Survival of the hypoxic cells was estimated by cell counting kit-8 assay. Expression alterations of the target hypoxia-related genes, cell cycle regulators, and apoptosis factors were investigated by Western blot.Results: According to the Gene Expression Omnibus dataset (GSE84538), differentiated embryo chondrocyte expressed gene 1-peroxisome proliferative-activated receptor-γ (Dec1-PPARγ) axis was defined as a key hypoxia-related signaling in PAH. A negative correlation was observed between Dec1 and PPARγ expression in patients with hypoxic PAH. In vitro observations revealed an increased proliferation and a decreased apoptosis in PAECs under hypoxia. Furthermore, hypoxic PAECs exhibited remarkable upregulation of Dec1 and downregulation of PPARγ. Dec1 was confirmed to be crucial for the imbalance of proliferation and apoptosis in hypoxic PAECs. Furthermore, the pro-surviving effect of hypoxic Dec1 was mediated through PPARγ inhibition.Conclusion: For the first time, Dec1-PPARγ axis was identified as a key determinant hypoxia-modifying signaling that is necessary for the imbalance between proliferation and apoptosis of PAECs. These novel endothelial signal transduction events may offer new diagnostic and therapeutic options for patients with hypoxic PAH.
Highlights
As a complex, progressive, and lethal disease, pulmonary arterial hypertension (PAH) is characterized by the increased muscularity of pulmonary arteries (PAs), resistance to blood flow, irreversible right ventricular (RV) failure, and premature death (Humbert et al, 2018)
Consistent with the results for distal PAs and pulmonary arterial endothelial cells (PAECs) from patients with PAH, differentiated embryo–chondrocyte-expressed gene 1 (Dec1) was elevated, but peroxisome proliferative-activated receptor-γ (PPARγ) was declined in a time-dependent manner when the cells were treated with serum deprivation (Figure 2C), H2O2 (Figure 2D), TGF-β1 (Figure 2E), and IL-6 (Figure 2F). These findings indicate that the Dec1–PPARγ axis can be disrupted by the PAH stimuli in vitro and may play critical roles in PAH progression
The results showed that the mRNA and protein levels of Dec1 were gradually increased in the Human normal PAECs (hnPAECs) with the extent of hypoxia (Figures 3A,B)
Summary
Progressive, and lethal disease, pulmonary arterial hypertension (PAH) is characterized by the increased muscularity of pulmonary arteries (PAs), resistance to blood flow, irreversible right ventricular (RV) failure, and premature death (Humbert et al, 2018). The morbidity and mortality of PAH increase dramatically with OSA severity (Adir et al, 2021). This interaction can be explained by the hypoxiainduced endothelial dysfunction, which is critical in vascular remodeling and vasoconstriction (Sehgal and Mukhopadhyay, 2007; Houten, 2015). The hypoxia-induced pro-proliferative and anti-apoptotic characteristics of pulmonary arterial endothelial cells (PAECs) play critical roles in pulmonary vascular remodeling and contribute to hypoxic pulmonary arterial hypertension (PAH) pathogenesis. The mechanism underlying this hypoxic disease has not been fully elucidated
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.